메뉴 건너뛰기




Volumn 360, Issue 1-2, 2010, Pages 30-38

Validation of an ELISA for the determination of rituximab pharmacokinetics in clinical trials subjects

Author keywords

CD20; Clinical trials; ELISA; Lymphoma; Rituximab; Validation

Indexed keywords

MONOCLONAL ANTIBODY; RITUXIMAB; CD20 ANTIGEN;

EID: 77955659493     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jim.2010.05.009     Document Type: Article
Times cited : (27)

References (29)
  • 2
    • 3142564395 scopus 로고    scopus 로고
    • Three new assays for rituximab based on its immunological activity or antigenic properties: analyses of sera and plasmas of RTX-treated patients with chronic lymphocytic leukemia and other B cell lymphomas
    • Beum P.V., Kennedy A.D., Taylor R.P. Three new assays for rituximab based on its immunological activity or antigenic properties: analyses of sera and plasmas of RTX-treated patients with chronic lymphocytic leukemia and other B cell lymphomas. J. Immunol. Meth. 2004, 289:97-109.
    • (2004) J. Immunol. Meth. , vol.289 , pp. 97-109
    • Beum, P.V.1    Kennedy, A.D.2    Taylor, R.P.3
  • 4
    • 4944220440 scopus 로고    scopus 로고
    • A new anti-idiotype antibody capable of binding rituximab on the surface of lymphoma cells
    • Cragg M.S., Bayne M.B., Tutt A.L., French R.R., Beers S., Glennie M.J., Illidge T.M. A new anti-idiotype antibody capable of binding rituximab on the surface of lymphoma cells. Blood 2004, 104:2540-2542.
    • (2004) Blood , vol.104 , pp. 2540-2542
    • Cragg, M.S.1    Bayne, M.B.2    Tutt, A.L.3    French, R.R.4    Beers, S.5    Glennie, M.J.6    Illidge, T.M.7
  • 7
    • 10744230729 scopus 로고    scopus 로고
    • Recommendations for the bioanalytical method validation of ligand-binding assays to support pharmacokinetic assessments of macromolecules
    • DeSilva B., Smith W., Weiner R., Kelley M., Smolec J., Lee B., Khan M., Tacey R., Hill H., Celniker A. Recommendations for the bioanalytical method validation of ligand-binding assays to support pharmacokinetic assessments of macromolecules. Pharm. Res. 2003, 20:1885-1900.
    • (2003) Pharm. Res. , vol.20 , pp. 1885-1900
    • DeSilva, B.1    Smith, W.2    Weiner, R.3    Kelley, M.4    Smolec, J.5    Lee, B.6    Khan, M.7    Tacey, R.8    Hill, H.9    Celniker, A.10
  • 9
    • 0003177157 scopus 로고    scopus 로고
    • Directive 2001/20/EC of the European Parliament and of the Council: on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practise in the conduct of clinical trials on medicinal products for human use
    • Fontaine N., Rosengren B. Directive 2001/20/EC of the European Parliament and of the Council: on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practise in the conduct of clinical trials on medicinal products for human use. OJEC 2001, 34-44.
    • (2001) OJEC , pp. 34-44
    • Fontaine, N.1    Rosengren, B.2
  • 14
    • 10344237546 scopus 로고    scopus 로고
    • Simple quantitative live cell and anti-idiotypic antibody based ELISA for humanized antibody directed to cell surface protein CD20
    • Hong K., Presta L.G., Lu Y., Penn A., Adams C., Chuntharapai A., Yang J., Wong W.L., Meng Y.G. Simple quantitative live cell and anti-idiotypic antibody based ELISA for humanized antibody directed to cell surface protein CD20. J. Immunol. Meth. 2004, 294:189-197.
    • (2004) J. Immunol. Meth. , vol.294 , pp. 189-197
    • Hong, K.1    Presta, L.G.2    Lu, Y.3    Penn, A.4    Adams, C.5    Chuntharapai, A.6    Yang, J.7    Wong, W.L.8    Meng, Y.G.9
  • 16
    • 61849136656 scopus 로고    scopus 로고
    • Phase 1/2 study of fractionated (131)I-rituximab in low-grade B-cell lymphoma: the effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy
    • Illidge T.M., Bayne M., Brown N.S., Chilton S., Cragg M.S., Glennie M.J., Du Y., Lewington V., Smart J., Thom J., Zivanovic M., Johnson P.W. Phase 1/2 study of fractionated (131)I-rituximab in low-grade B-cell lymphoma: the effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy. Blood 2009, 113:1412-1421.
    • (2009) Blood , vol.113 , pp. 1412-1421
    • Illidge, T.M.1    Bayne, M.2    Brown, N.S.3    Chilton, S.4    Cragg, M.S.5    Glennie, M.J.6    Du, Y.7    Lewington, V.8    Smart, J.9    Thom, J.10    Zivanovic, M.11    Johnson, P.W.12
  • 24
    • 34247894006 scopus 로고    scopus 로고
    • Best practices during bioanalytical method validation for the characterization of assay reagents and the evaluation of analyte stability in assay standards, quality controls, and study samples
    • Nowatzke W., Woolf E. Best practices during bioanalytical method validation for the characterization of assay reagents and the evaluation of analyte stability in assay standards, quality controls, and study samples. AAPS J. 2007, 9:E117-E122.
    • (2007) AAPS J. , vol.9
    • Nowatzke, W.1    Woolf, E.2
  • 29
    • 43949156757 scopus 로고
    • CD20: a regulator of cell-cycle progression of B lymphocytes
    • Tedder T.F., Engel P. CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol. Today 1994, 15:450-454.
    • (1994) Immunol. Today , vol.15 , pp. 450-454
    • Tedder, T.F.1    Engel, P.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.